Login to Your Account



China Revokes Gilead's Viread Patent; Pricing Is at Issue

By Shannon Ellis
Staff Writer

Wednesday, August 7, 2013
SHANGHAI – A year after China introduced an amended patent law, authorities have revoked the patent on Gilead Science Inc.'s HIV/AIDS and hepatitis B drug Viread (tenofovir disoproxil fumarate).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription